Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • Guaranteed Paid Placement
  • SocialBoost
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • SocialBoost
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Watchdog Group: Medicaid's Child Psychotropic Drugging Needs Greater Oversight

Protections needed to protect children from adverse effects of antidepressants, antipsychotics, anti-anxiety drugs and psychostimulants


News provided by

Citizens Commission on Human Rights International

Jul 18, 2017, 09:00 ET

Share this article

Share toX

Share this article

Share toX

LOS ANGELES, July 18, 2017 /PRNewswire/ -- The mental health watchdog Citizens Commission on Human Rights (CCHR) applauded the recent Department of Justice health care fraud crackdown but says greater oversight is needed of Medicaid billing of psychotropic drugs prescribed children, which could reduce their use and increase protections.

Continue Reading
psychiatric drugging of children
psychiatric drugging of children

In announcing a national health care fraud takedown by the U.S. Department of Justice (DOJ) on July 13, 2017, Attorney General Jeff Sessions said that, "Too many trusted medical professionals like doctors, nurses, and pharmacists have chosen to violate their oaths and put greed ahead of their patients."[1] Citizens Commission on Human Rights, which has investigated abuses in the mental health system for 48 years, applauded the crackdown but says a key area of investigation should be the psychotropic drugging of children under Medicaid.

The number of children taking powerful antipsychotic drugs has nearly tripled over the last 10 to 15 years, according to a consumer report. The increase, the report says, comes from the drugs being increasingly prescribed to treat behavior problems, a use not approved by the Food and Drug Administration (FDA).[2]

CCHR says that prescribing patterns under Medicaid should be investigated to isolate where psychotropic drug prescriptions to children and adolescents is most prevalent, reduce that number to safeguard this population, and, in doing so help to reduce Medicaid costs. In one year alone, Medicaid spent about $8 billion in fee for service for psychotropic drugs for all age groups — 30 percent of the program's total fee-for-service drug spending for all age groups.[3]

In 2014, the Government Accountability Office (GAO) found the federal government and states had taken a multitude of steps to better oversee psychotropic drug prescribing for children in foster care.[4] A GAO drug audit had uncovered a 2,200 percent increase in drug expenditures for atypical antipsychotic drug reimbursement to the state of Michigan alone between 2000 and 2008. The Michigan Medicaid system was billed an increase of $40 million during the eight-year period just for this one class of drugs for foster children.[5]

CCHR says that despite Federal plans for state oversight of foster care drugging, the problem persists — possibly because of the profits involved for prescribers and youth behavioral facilities. For example, in 2013, Missouri adopted a pilot "second opinion" program, in which a board-certified child psychiatrist was tasked with reviewing the prescriptions for 10 children and searching for trends in how these medications are used. Three years later, however, in its 2016 report to the federal government, Missouri's Department of Social Services admitted that "many foster care children are prescribed multiple psychotropic medications without clear evidence of benefit and with inadequate safety data. The use of multiple medications (psychotropic or otherwise) creates the potential for serious drug interactions."[6]

In 2015, the Medicaid and CHIP Payment and Access Commission (MACPAC) report on "Use of Psychotropic Medications among Medicaid Beneficiaries" found nearly one-quarter (24 percent) of children eligible based on child welfare assistance used a psychotropic drug, almost five times the rate of children eligible on a basis other than disability or child welfare assistance (5 percent).[7]

"The high rates of psychotropic medication use in the Medicaid population, risks associated with these drugs, and research documenting inappropriate prescribing, have raised concerns, especially for children involved in the child welfare system," according to the MACPAC report.[8]

Another 2015 report by the U.S. Department of Health and Human Services (HHS) Inspector General examined in depth nearly 700 claims filed in five of the biggest prescribing states — California, Florida, Illinois, Texas and New York — and discovered that two thirds of all the prescribing with costly "second generation antipsychotics" raised high-risk "quality of care" concerns.[9]

The report noted several disturbing examples:

  • A 10 year old given an antipsychotic — without any medical documentation — mixed in with other psych drugs;
  • A 4 year old on four psychotropic drugs, including two antipsychotics;
  • A 16 year old on six psychiatric drugs, including three antipsychotics.

In the latter case, among the side effects of this polypharmacy assault, The Huffington Post reported: "This child experienced paranoia, hostility, unstable mood, hallucinations, and suicidal thoughts. This child also experienced significant side effects potentially resulting from the prescribed drugs, including a 22-pound weight gain, insomnia, and edema (swelling) of hands and feet."[10]

The report also noted that over half of kids receiving antipsychotics are victimized by "poor monitoring" of the drugs' risky health side effects— which can include breast growth in boys, cardiac arrest, extreme weight gain and diabetes.[11]

CCHR emphasizes that oversight is also needed in the private-for-profit behavioral sector where children are treated often at a cost to Medicaid. One large behavioral health company has significant reimbursement (33 percent) from Medicaid, "substantially all" of which relates to the treatment of children and adolescents. The company estimated that the child and adolescent behavioral healthcare market was $11 billion in 2014.

According to the IMS, Vector One: National and Total Patient Tracker Database for 2013, more than 274,000 0-1 year olds were prescribed psychiatric drugs and a staggering 370,000 toddlers. Over 3,760 two to three year olds were on antipsychotics; 46,102 were taking antidepressants and 282,759 were on anti-anxiety drugs. Additionally, 500,948 four to five year olds were on prescription psychotropic drugs, more than 4.1 million six to twelve year olds and greater than 3.6 million aged between 13 and 17.[12]

CCHR says potential prescription abuse, such as off-label (prescribed for unapproved use) was also highlighted by a 2012 study where national data showed a dramatic rise in off-label and FDA-approved uses of these drugs. Of particular note was a twofold to fivefold increase in the use of antipsychotic drugs in preschool children, despite little information on their long-term effects. Researchers from Johns Hopkins University concluded that although an increase in the off-label use of antipsychotic medications in children and adolescents had occurred, no standardized oversight exists to guide such use.[13]

A New York Times article on the risk of antipsychotics in children said, "Many doctors say prescribing them for younger and younger children may pose grave risks to development of both their fast-growing brains and their bodies. Doctors can legally prescribe them for off-label use, including in preschoolers, even though research has not shown them to be safe or effective for children."[14]

"What's not known about the long-term effects is very troubling," Christopher Bellonci, M.D., assistant professor at Tufts University School of Medicine in Boston, said. "The younger you go, the more you can affect the developing brain."[15]

CCHR wants to see the oversight of the drug prescription practices increased, especially when it relates to children and adolescents who need greater protections. As Edward Opton with the National Center for Youth Law's PsychDrugs Action Campaign, said: "Foster children are a lucrative market for psychotropic drug sales. Unlike adults, they can't say, 'No, I won't take any more of that drug.'"[16] The same can be said for all children, CCHR adds. Frequently, parents are not fully informed of psychotropic drug risks, which is why CCHR is committed to providing information to improve informed consent rights.

As a nonprofit, CCHR relies on memberships and donations to carry out its mission and actions to curb psychotropic drug use in children, including foster care youths. Click here to support the cause. It has already been responsible for helping get over 180 laws enacted, including the 2004 Federal Prohibition on Mandatory Medication Amendment that prohibits schools from forcing children to take psychotropic drugs as a requisite for their education.

Contact: Amber Rauscher, [email protected] or (323) 467-4242.

[1] "Sessions announces 'largest health care fraud takedown' in U.S. history," CBS News, 13 July 2017, http://www.cbsnews.com/news/sessions-announces-largest-health-care-fraud-take-down-in-us-history/

[2] "Are too many kids taking antipsychotic drugs?: Use is climbing despite questions about how safe the drugs are and how well they work" Consumer Reports, Dec. 2013 http://www.consumerreports.org/cro/2013/12/are-too-many-kids-taking-antipsychotic-drugs/index.htm

[3] Chapter 5, "Use of Psychotropic Medications among Medicaid Beneficiaries," Medicaid and CHIP Payment and Access Commission (MACPAC), June 2015, https://www.macpac.gov/wp-content/uploads/2015/06/Use-of-Psychotropic-Medications-among-Medicaid-Beneficiaries.pdf

[4] https://www.gao.gov/products/GAO-14-651T

[5] Frank J. Granett, R.ph, Director of Clinical Pharmacy Operations at Behavioral Center of Michigan Psychiatric Hospital, Author: Over Medicating Our Youth & The American Epidemic "The Price of ADHD Business," Op Ed News.com, 9 Feb., 2014, http://www.opednews.com/articles/The-Price-of-ADHD-Business-by-Frank-J-Granett-R-Children_Children-Teens_Depression_Diagnosis-140209-373.html

[6] http://www.newsweek.com/missouri-drugs-foster-children-keep-them-docile-628575

[7] Chapter 5, "Use of Psychotropic Medications among Medicaid Beneficiaries," Medicaid and CHIP Payment and Access Commission (MACPAC), June 2015, https://www.macpac.gov/wp-content/uploads/2015/06/Use-of-Psychotropic-Medications-among-Medicaid-Beneficiaries.pdf

[8] Chapter 5, "Use of Psychotropic Medications among Medicaid Beneficiaries," Medicaid and CHIP Payment and Access Commission (MACPAC), June 2015, https://www.macpac.gov/wp-content/uploads/2015/06/Use-of-Psychotropic-Medications-among-Medicaid-Beneficiaries.pdf

[9] "Feds Pay for Drug Fraud: 92 Percent of Foster Care, Poor Kids Prescribed Antipsychotics Get Them for Unaccepted Uses," Huffington Post, 30 May, 2015, http://www.huffingtonpost.com/art-levine/feds-pay-for-drug-fraud-9_b_6966454.html

[10] "Feds Pay for Drug Fraud: 92 Percent of Foster Care, Poor Kids Prescribed Antipsychotics Get Them for Unaccepted Uses," Huffington Post, 30 May, 2015, http://www.huffingtonpost.com/art-levine/feds-pay-for-drug-fraud-9_b_6966454.html

[11] "Feds Pay for Drug Fraud: 92 Percent of Foster Care, Poor Kids Prescribed Antipsychotics Get Them for Unaccepted Uses," Huffington Post, 30 May, 2015, http://www.huffingtonpost.com/art-levine/feds-pay-for-drug-fraud-9_b_6966454.html

[12] IMS, Vector One: National (VONA) and Total Patient Tracker (TPT) Database, Year 2013, Extracted April 2014

[13] "Antipsychotic Medication Prescribing Trends in Children and Adolescents, J Pediatr Health Care. 2012 Mar; 26(2): 139–145; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778027

[14] "Child's Ordeal Shows Risks of Psychosis Drugs for Young," The New York Times, 1 Sept., 2010, http://www.nytimes.com/2010/09/02/business/02kids.html

[15] "Are too many kids taking antipsychotic drugs?: Use is climbing despite questions about how safe the drugs are and how well they work" Consumer Reports, Dec. 2013 http://www.consumerreports.org/cro/2013/12/are-too-many-kids-taking-antipsychotic-drugs/index.htm

[16] http://www.huffingtonpost.com/art-levine/feds-pay-for-drug-fraud-9_b_6966454.html

SOURCE Citizens Commission on Human Rights International

Related Links

https://www.cchrint.org

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.